Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 22, Issue 13, pp. 3238-3248
PubMed
Published By
Print ISSN
Online ISSN
History
- Received January 11, 2016
- Revision received April 13, 2016
- Accepted April 13, 2016
- Published first June 1, 2016.
Article Versions
- Previous version (June 1, 2016 - 08:52).
- You are viewing the most recent version of this article.
Copyright & Usage
©2016 American Association for Cancer Research.
Author Information
- Pierre Van Damme1,*,
- Myriam Bouillette-Marussig2,
- Annick Hens1,
- Ilse De Coster1,
- Christophe Depuydt3,
- Anne Goubier4,
- Viggo Van Tendeloo1,
- Nathalie Cools1,
- Herman Goossens1,
- Thierry Hercend5,
- Benedikt Timmerman6, and
- Marie-Christine Bissery2
- 1University of Antwerp, Antwerp, Belgium.
- 2Genticel, Paris, France.
- 3Department of Molecular Diagnostics, AML, Sonic Healthcare, Antwerp, Belgium.
- 4Tusk Therapeutics, Meise, Belgium.
- 5Edmond de Rothschild Investment Partners, Paris, France.
- 6Genticel, Labège, France.
- ↵*Corresponding Author:
Pierre Van Damme, University of Antwerp, Universiteitsplein 1, Wilrijk, Antwerp 2610, Belgium. Phone: 32 3265-2538; Fax: 32 3265-2640; E-mail: pierre.vandamme{at}uantwerpen.be
July 2016
Volume 22, Issue 13
Volume 22, Issue 13
GTL001, A Therapeutic Vaccine for Women Infected with Human Papillomavirus 16 or 18 and Normal Cervical Cytology: Results of a Phase I Clinical Trial
Jump to section
Advertisement